المؤلفون: Jacobien R. Hilberink, Isabelle A. van Zeventer, Dana A. Chitu, Thomas Pabst, Saskia K. Klein, Georg Stussi, Laimonas Griskevicius, Peter J. M. Valk, Jacqueline Cloos, Arjan A. van de Loosdrecht, Dimitri Breems, Danielle van Lammeren-Venema, Rinske Boersma, Mojca Jongen-Lavrencic, Martin Fehr, Mels Hoogendoorn, Markus G. Manz, Maaike Söhne, Rien van Marwijk Kooy, Dries Deeren, Marjolein W. M. van der Poel, Marie Cecile Legdeur, Lidwine Tick, Yves Chalandon, Emanuele Ammatuna, Sabine Blum, Bob Löwenberg, Gert J. Ossenkoppele, Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON), Swiss Group for Clinical Cancer Research (SAKK), Gerwin Huls

المصدر: Blood Cancer Journal, Vol 13, Iss 1, Pp 1-9 (2023)

مصطلحات موضوعية: Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

Relation: https://doaj.org/toc/2044-5385

URL الوصول: https://doaj.org/article/71614de5d82b474e855269ada1ea2dee

المؤلفون: Dietger Niederwieser, Dirk Hasenclever, Wolfgang E. Berdel, Bart J. Biemond, Haifa Kathrin Al-Ali, Yves Chalandon, Michel Van Gelder, Christian Junghanss, Goesta Gahrton, Mathias Haenel, Rüdiger Hehlmann, Thomas Heinicke, Andreas Hochhaus, Simona Iacobelli, Rien van Marwijk Kooy, Nicolaus Kröger, Jeroen J.W.M. Janssen, Madlen Jentzsch, Frank Breywisch, Mohamad Mohty, Stavroula Masouridi-Levrat, Gert Ossenkoppele, Jakob Passweg, Wolfram Pönisch, Johannes Schetelig, Christoph Schliemann, Sebastian Schwind, Matthias Stelljes, Peter JM Valk, Bob Lowenberg, Jan J. Cornelissen

المصدر: Blood. 140:2126-2129

مصطلحات موضوعية: Immunology, Cell Biology, Hematology, Biochemistry

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::54fc73dfad3387acaa0e6311028d8a55
https://doi.org/10.1182/blood-2022-157684

المؤلفون: Rien van Marwijk Kooy, Gert J. Ossenkoppele, Arjan A. van de Loosdrecht, Wim Terpstra, Dana A. Chitu, Okke de Weerdt, Dimitri Breems, Bob Löwenberg, Jürgen Kuball, Marie-Christiane Vekemans, Edo Vellenga, Dries Deeren, Bart J. Biemond, Gerwin Huls, Saskia K. Klein, Harm Sinnige, Violaine Havelange, Mojca Jongen-Lavrencic, Beata Hodossy, Carlos Graux

المساهمون: UCL - SSS/DDUV/MEXP - Médecine expérimentale, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - (MGD) Service d'hématologie, UCL - (SLuc) Service d'hématologie, CCA - Cancer Treatment and quality of life, Hematology, CCA - Cancer Treatment and Quality of Life, Clinical Haematology, Stem Cell Aging Leukemia and Lymphoma (SALL), Guided Treatment in Optimal Selected Cancer Patients (GUTS)

المصدر: Blood, 133, 13, pp. 1457-1464
Blood, Vol. 133, no. 13, p. 1457-1464 (2019)
Huls, G, Chitu, D A, Havelange, V, Jongen-Lavrencic, M, van de Loosdrecht, A A, Biemond, B J, Sinnige, H, Hodossy, B, Graux, C, Kooy, R V M, de Weerdt, O, Breems, D, Klein, S, Kuball, J R, Deeren, D, Terpstra, W, Vekemans, M-C, Ossenkoppele, G J, Vellenga, E, Löwenberg, B & Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) 2019, ' Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients ', Blood, vol. 133, no. 13, pp. 1457-1464 . https://doi.org/10.1182/blood-2018-10-879866
Blood, 133(13), 1457-1464. American Society of Hematology
Blood, 133, 1457-1464
Blood, 133(13), 1457-1464. AMER SOC HEMATOLOGY
Blood, 133(13), 1457. American Society of Hematology

مصطلحات موضوعية: Myeloid, Oncology, Male, Antimetabolites, Antineoplastic, medicine.medical_specialty, Randomization, Antimetabolites, Azacitidine, Immunology, Azacitidine/therapeutic use, Leukemia, Myeloid, Acute/drug therapy, Phases of clinical research, Research Support, Antineoplastic/therapeutic use, Biochemistry, Disease-Free Survival, Maintenance Chemotherapy, All institutes and research themes of the Radboud University Medical Center, Internal medicine, 80 and over, medicine, Journal Article, Acute/drug therapy, Humans, Non-U.S. Gov't, Aged, Aged, 80 and over, Leukemia, business.industry, Proportional hazards model, Research Support, Non-U.S. Gov't, Hazard ratio, Remission Induction, Age Factors, Cell Biology, Hematology, Middle Aged, medicine.disease, Antimetabolites, Antineoplastic/therapeutic use, Chemotherapy regimen, Clinical Trial, Transplantation, Leukemia, Myeloid, Acute, Inflammatory diseases Radboud Institute for Health Sciences [Radboudumc 5], Female, Refractory anemia with excess of blasts, business, medicine.drug

وصف الملف: image/pdf; application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86ec6abfc1914fed725c01b2fea11bdb
https://research.rug.nl/en/publications/b98e4189-e14b-41d3-842e-499110bd4147

المؤلفون: Peter J. M. Valk, Yves Chalandon, Thomas Pabst, Markus G. Manz, Dimitri Breems, Maaike Sohne, Bob Löwenberg, Emanuele Ammatuna, Marjolein van der Poel, Sabine Blum, Dries Deeren, Rien van Marwijk Kooy, Dana A. Chitu, Mojca Jongen-Lavrencic, Lidwine W. Tick, Marie Cecile J.C. Legdeur, Gerwin Huls, Saskia K. Klein, Danielle van Lammeren-Venema, Gert J. Ossenkoppele, Georg Stussi, Arjan A. van de Loosdrecht, Isabelle A van Zeventer, Rinske S. Boersma, M. Fehr, Mels Hoogendoorn, Jacqueline Cloos, Laimonas Griskevicius

المساهمون: Stem Cell Aging Leukemia and Lymphoma (SALL), Guided Treatment in Optimal Selected Cancer Patients (GUTS), Hematology laboratory, CCA - Cancer Treatment and quality of life, Hematology, University of Zurich, Huls, Gerwin, Interne Geneeskunde, MUMC+: MA Hematologie (9), RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy

المصدر: Blood advances, vol. 4, no. 18, pp. 4267-4277
Blood Advances, Vol. 4, No 18 (2020) pp. 4267-4277
Blood, 4(18), 4267-4277. AMER SOC HEMATOLOGY
Blood, 4(18), 4267-4277. American Society of Hematology
Blood advances, 4(18), 4267-4277. American Society of Hematology
Huls, G, Chitu, D A, Pabst, T, Klein, S K, Stussi, G, Griskevicius, L, Valk, P J M, Cloos, J, van de Loosdrecht, A A, Breems, D, van Lammeren-Venema, D, van Zeventer, I, Boersma, R, Jongen-Lavrencic, M, Fehr, M, Hoogendoorn, M, Manz, M G, Söhne, M, Kooy, R V M, Deeren, D, van der Poel, M W M, Legdeur, M C, Tick, L, Chalandon, Y, Ammatuna, E, Blum, S, Löwenberg, B & Ossenkoppele, G J 2020, ' Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS ', Blood, vol. 4, no. 18, pp. 4267-4277 . https://doi.org/10.1182/BLOODADVANCES.2020002846
Blood advances, 4(18), 4267-4277. The American Society of Hematology
Blood Adv

مصطلحات موضوعية: Oncology, medicine.medical_specialty, Clinical Trials and Observations, medicine.medical_treatment, 2720 Hematology, Decitabine, MINIMAL RESIDUAL DISEASE, 610 Medicine & health, Hematopoietic stem cell transplantation, ACUTE MYELOID-LEUKEMIA, chemistry.chemical_compound, Piperidines, Internal medicine, CONVENTIONAL CARE REGIMENS, AZACITIDINE THERAPY, Humans, Medicine, Adverse effect, TREATMENT RESPONSE, Netherlands, MYELODYSPLASTIC SYNDROME, ddc:616, business.industry, Adenine, CLINICAL-RESPONSE, Myeloid leukemia, Hematology, Minimal residual disease, Transplantation, Leukemia, Myeloid, Acute, chemistry, Tolerability, HYPOMETHYLATING AGENT THERAPY, Myelodysplastic Syndromes, Ibrutinib, 10032 Clinic for Oncology and Hematology, SURVIVAL, TRIAL, business, medicine.drug

وصف الملف: application/pdf; advancesadv2020002846.pdf - application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f035f8641df261cae7346abf960dbaaf
https://serval.unil.ch/notice/serval:BIB_BA95A00DDE07

المؤلفون: Lotte E, van der Wagen, Alberto, Miranda-Bedate, Anke, Janssen, Febilla, Fernando, Nagesha, Appukudige, Sanne, van Dooremalen, Kasper, Westinga, Rick, Admiraal, Magdalena J, Lorenowicz, Gerwin, Huls, Jeroen J W M, Janssen, Annoek E C, Broers, Walter J F M, van der Velden, Rien, van Marwijk Kooy, Mette D, Hazenberg, Colin, de Haar, Caroline, Lindemans, Jaap, Jan Boelens, Jürgen, Kuball

المصدر: Bone marrow transplantation. 55(11)

مصطلحات موضوعية: Acute Disease, Hematopoietic Stem Cell Transplantation, Graft vs Host Disease, Humans, Mesenchymal Stem Cells, Steroids, Mesenchymal Stem Cell Transplantation, Tissue Donors

URL الوصول: https://explore.openaire.eu/search/publication?articleId=pmid________::76595d1970b7d431a555eef5a68f2322
https://pubmed.ncbi.nlm.nih.gov/32346077

المؤلفون: Colin de Haar, Kasper Westinga, Mette D. Hazenberg, Caroline A. Lindemans, Sanne van Dooremalen, Rick Admiraal, Lotte van der Wagen, Jürgen Kuball, Magdalena J. Lorenowicz, Anke Janssen, Jaap Jan Boelens, Walter J.F.M. van der Velden, Febilla Fernando, Nagesha Appukudige, Rien van Marwijk Kooy, Annoek E.C. Broers, Jeroen Janssen, Gerwin Huls, Alberto Miranda-Bedate

المساهمون: Hematology, Graduate School, Amsterdam Reproduction & Development (AR&D), Clinical Haematology, Stem Cell Aging Leukemia and Lymphoma (SALL), Guided Treatment in Optimal Selected Cancer Patients (GUTS)

المصدر: Bone Marrow Transplantation, 55, 2188-2192
Bone Marrow Transplantation, 55(11), 2188-2192. Nature Publishing Group
Bone marrow transplantation, 55(11), 2188-2192. Nature Publishing Group
van der Wagen, L E, Miranda-Bedate, A, Janssen, A, Fernando, F, Appukudige, N, van Dooremalen, S, Westinga, K, Admiraal, R, Lorenowicz, M J, Huls, G, Janssen, J J W M, Broers, A E C, van der Velden, W J F M, van Marwijk Kooy, R, Hazenberg, M D, de Haar, C, Lindemans, C, Jan Boelens, J & Kuball, J 2020, ' Efficacy of MSC for steroid-refractory acute GVHD associates with MSC donor age and a defined molecular profile ', Bone Marrow Transplantation, vol. 55, no. 11, pp. 2188-2192 . https://doi.org/10.1038/s41409-020-0910-9
Bone Marrow Transplantation, 55, 11, pp. 2188-2192

مصطلحات موضوعية: Transplantation, business.industry, medicine.medical_treatment, Mesenchymal stem cell, Hematology, Hematopoietic stem cell transplantation, Donor age, MESENCHYMAL STEM-CELLS, Gene expression, Inflammatory diseases Radboud Institute for Health Sciences [Radboudumc 5], Cancer research, Medicine, Molecular Profile, business, Steroid refractory, GENE-EXPRESSION

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07b48fc123a55f88a9f68c16049df95b
http://hdl.handle.net/2066/229413

المؤلفون: Wendy Deenik, Willem M. Smit, Jeroen Janssen, Noortje Thielen, Gert J. Ossenkoppele, Pieter Sonneveld, Gregor Verhoef, Peter J. M. Valk, J.H. Frederik Falkenburg, Harm Sinnige, Rianne A. H. M. Ammerlaan, Anton Schattenberg, Isabel W. T. Chu, M. Schipperus, Bronno van der Holt, Jan J. Cornelissen, Rien van Marwijk Kooy, Marie José Kersten

المساهمون: AII - Amsterdam institute for Infection and Immunity, CCA -Cancer Center Amsterdam, Clinical Haematology, Hematology, CCA - Innovative therapy

المصدر: Annals of Hematology, 92, 8, pp. 1049-56
Thielen, N, van der Holt, B, Verhoef, G E G, Ammerlaan, R A H M, Sonneveld, P, Janssen, J J W M, Deenik, W, Falkenburg, J H F, Kersten, M J, Sinnige, H A M, Schipperus, M, Schattenberg, A, Kooy, R V, Smit, W M, Chu, I W T, Valk, P J M, Ossenkoppele, G J & Cornelissen, J J 2013, ' High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch-Belgian HOVON study group ', Annals of Hematology, vol. 92, no. 8, pp. 1049-1056 . https://doi.org/10.1007/s00277-013-1730-4
Annals of hematology, 92(8), 1049-1056. Springer Verlag
Annals of Hematology, 92(8), 1049-1056. Springer Verlag
Annals of Hematology, 92(8), 1049-1056
Annals of Hematology, 92, 1049-56

مصطلحات موضوعية: Oncology, Adult, Male, medicine.medical_specialty, Adolescent, Gastrointestinal Diseases, Pain, Kaplan-Meier Estimate, Infections, Major molecular response, Disease-Free Survival, Piperazines, Young Adult, Translational research [ONCOL 3], Internal medicine, hemic and lymphatic diseases, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Young adult, Adverse effect, Protein Kinase Inhibitors, Aged, Hematology, business.industry, Chronic myeloid leukemia, Cytarabine, Myeloid leukemia, Imatinib, General Medicine, Middle Aged, Hematologic Diseases, Surgery, Pyrimidines, Treatment Outcome, Major Molecular Response, Sample Size, Benzamides, Early Termination of Clinical Trials, Leukemia, Myeloid, Chronic-Phase, Imatinib Mesylate, Female, business, Tyrosine kinase, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6fb5649d7382925fb68cdb50d11ac25d
https://doi.org/10.1007/s00277-013-1730-4

المؤلفون: Mark H.H Kramer, Monique Steijaert, Bob Löwenberg, Pierre W. Wijermans, Rien van Marwijk Kooy, Peter C. Huijgens, Gregor Verhoef, Simon Daenen, Harry C. Schouten, Leo F. Verdonck, Bronno van der Holt, Pieter Sonneveld, Augustin Ferrant, Eva van den Berg

المصدر: Leukemia Research. 28:1057-1067

مصطلحات موضوعية: Oncology, Cancer Research, Chemotherapy, medicine.medical_specialty, Mitoxantrone, business.industry, medicine.medical_treatment, Hematology, Transplantation, Refractory, Cyclosporin a, Internal medicine, Toxicity, Medicine, business, Survival analysis, Etoposide, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::98801ec81daac69a558cafa61ff90115
https://doi.org/10.1016/j.leukres.2004.03.001

المؤلفون: Canan Alhan, Marie-Cecile Legdeur, Petra Muus, Edo Vellenga, Dana A. Chitu, Bea Tanis, Saskia K. Klein, Inge de Greef, Heleen Visser-Wisselaar, Gert J. Ossenkoppele, Arjan A. van de Loosdrecht, Jurgen Wegman, Annelies Verbrugge, Wendy Deenik, Eline M. P. Cremers, Theresia M. Westers, Mojca Jongen-Lavrencic, Rien van Marwijk-Kooy, Tanja van Maanen, Joop H. Jansen, Pierre W. Wijermans

المصدر: Blood. 128:224-224

مصطلحات موضوعية: 0301 basic medicine, medicine.medical_specialty, Blood transfusion, medicine.medical_treatment, Immunology, Phases of clinical research, Biochemistry, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, Refractory, Internal medicine, Medicine, Adverse effect, Lenalidomide, business.industry, Cell Biology, Hematology, Surgery, Granulocyte colony-stimulating factor, 030104 developmental biology, Erythropoietin, 030220 oncology & carcinogenesis, Erythropoietin Measurement, business, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::83c2e69e928193f37985c8084d27cf0c
https://doi.org/10.1182/blood.v128.22.224.224

المؤلفون: Bronno van der Holt, Eefke Petersen, Simon Daenen, Jeroen Janssen, Gert J. Ossenkoppele, Willem M. Smit, Titia Gussinklo, Bart J. Biemond, Peter J. M. Valk, Wendy Deenik, Jan J. Cornelissen, Noortje Thielen, Gregor Verhoef, Rien van Marwijk Kooy

المساهمون: AII - Amsterdam institute for Infection and Immunity, CCA -Cancer Center Amsterdam, Clinical Haematology, Hematology, CCA - Innovative therapy

المصدر: European journal of cancer (Oxford, England, 49(15), 3242-3246. Elsevier Limited
Thielen, N, van der Holt, B, Cornelissen, J J, Verhoef, G E G, Gussinklo, T, Biemond, B J, Daenen, S M G, Deenik, W, Kooy, R V, Petersen, E, Smit, W M, Valk, P J M, Ossenkoppele, G J & Janssen, J J W M 2013, ' Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: A randomised trial of the Dutch-Belgian Cooperative Trial for Haemato-Oncology (HOVON) ', European Journal of Cancer, vol. 49, no. 15, pp. 3242-3246 . https://doi.org/10.1016/j.ejca.2013.06.018
European Journal of Cancer, 49(15), 3242-3246. ELSEVIER SCI LTD
European Journal of Cancer, 49(15), 3242-3246. Pergamon
European Journal of Cancer, 49(15), 3242-3246. Elsevier Ltd.

مصطلحات موضوعية: Oncology, Male, Cancer Research, THERAPY, Piperazines, NEWLY-DIAGNOSED PATIENTS, Belgium, hemic and lymphatic diseases, CML, Netherlands, Complete molecular response, CHRONIC MYELOGENOUS LEUKEMIA, QUIESCENT, Remission Induction, MESYLATE DISCONTINUATION, CYTARABINE, Survival Rate, Treatment Outcome, Benzamides, Leukemia, Myeloid, Chronic-Phase, Imatinib Mesylate, Female, STEM-CELLS, Tyrosine kinase, medicine.drug, medicine.medical_specialty, Combination therapy, Alpha interferon, Discontinuation, Disease-Free Survival, Drug Administration Schedule, Median follow-up, Internal medicine, medicine, Humans, neoplasms, Protein Kinase Inhibitors, Chronic myeloid leukaemia, business.industry, Imatinib, REMISSION, medicine.disease, Pyrimidines, Cytarabine, INTERFERON-ALPHA, Neoplasm Recurrence, Local, business, Chronic myelogenous leukemia

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba26a9de363d7e8c69ffd453870d99a3
https://pubmed.ncbi.nlm.nih.gov/23876833